Reduced COVID-19 Mortality With Sitagliptin Treatment? Weighing the Dissemination of Potentially Lifesaving Findings Against the Assurance of High Scientific Standards

What is it about?

Even in the special situation of a pandemic, when rapid advancement of knowledge is of prime importance, assurance of a high scientific quality istandard should not be neglected. This commentary scrutinizes an observational study suggesting benefits of treating COVID-19 patients with type 2 diabetes with sitagliptin, a DPP-4 inhibitor to illustrate the necessary balance between timely publication and thorrough assessment of limitations.

Featured Image